(Q37766747)

22 August 2017

1 reference

title

Novel therapeutic targets for hypertension (English)

1 reference

22 August 2017

arterial hypertension

0 references

2

Thomas Unger

1 reference

22 August 2017

1

Ludovit Paulis

1 reference

PubMed ID

20567239

22 August 2017

language of work or name

English

0 references

publication date

22 June 2010

1 reference

Nature Reviews Cardiology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

8

1 reference

22 August 2017

431-441

1 reference

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Signal transduction from the angiotensin II AT2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Vasopeptidase Inhibition Prevents Endothelial Dysfunction of Resistance Arteries in Salt-Sensitive Hypertension in Comparison With Single ACE Inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Translational medicine: the antihypertensive effect of renal denervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effects of intensive blood-pressure control in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Hypertension treatment and control in five European countries, Canada, and the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

The role of the renin-angiotensin system in the development of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Telmisartan, ramipril, or both in patients at high risk for vascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Beyond the classic angiotensin-receptor-blocker profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Next generation multifunctional angiotensin receptor blockers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Drugs targeting the renin-angiotensin-aldosterone system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

PLZF and the (pro)renin receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

The AT2 receptor--a matter of love and hate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Adapter proteins and promoter regulation of the angiotensin AT2 receptor--implications for cardiac pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Molecular and cellular mechanism of angiotensin II-mediated apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Vasopeptidase inhibition: a double-edged sword?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effects of omapatrilat in low, normal, and high renin experimental hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Efficacy and tolerance of spironolactone in essential hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Aldosterone: role in the cardiometabolic syndrome and resistant hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Association of adrenal steroids with hypertension and the metabolic syndrome in blacks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Hyperaldosteronism among black and white subjects with resistant hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effects of eplerenone versus losartan in patients with low-renin hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Mineralocorticoid receptors: distribution and activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Possible roles of human (pro)renin receptor suggested by recent clinical and experimental findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Catecholamines regulate the activity, secretion, and synthesis of renalase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Regulation of blood pressure and cardiovascular function by renalase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Renalase, a catecholamine-metabolizing hormone from the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Sympathectomy in the treatment of hypertension; review of 122 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Splanchnicectomy for essential hypertension; results in 1,266 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Renal sympathetic-nerve ablation for uncontrolled hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Recent developments in nitric oxide donor drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

NO-independent stimulators of soluble guanylate cyclase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Tadalafil therapy for pulmonary arterial hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Phosphodiesterase-5 inhibitors and their hemodynamic effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Drospirenone, a new progestogen, for postmenopausal women with hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.85

Cardiovascular diseases: protective effects of melatonin

31 March 2020

1 reference

12 December 2020

Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind

1 reference

12 December 2020

Pharmacologic treatment for pulmonary arterial hypertension

1 reference

12 December 2020

The role of sildenafil in the treatment of stroke

1 reference

12 December 2020

Oral tadalafil in pulmonary artery hypertension: a prospective study

1 reference

12 December 2020

Antihypertensive drug therapy and survival by treatment status in a national survey

1 reference

12 December 2020

Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats

1 reference

12 December 2020

Antirenin in man and animals

1 reference

12 December 2020

Omapatrilat. Bristol-Myers Squibb.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2010.85

1 reference

22 August 2017

1 reference

PubMed ID

20567239